Latest:
Dr Maese on Asparaginase-Based Regimens in Adult/Young Adult ALL
Luke Maese, DO, discusses treatment considerations for asparaginase-containing regimens in adult and young adult patients with ALL.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Haifaa Abdulhaq, MD
Latest:
Future Perspectives for the Treatment of Relapsed/Refractory DLBCL
A reflection on key accomplishments in DLBCL treatment, highlighting pivotal developments that have shaped clinical practice, followed by a look ahead to 2025, focusing on areas poised for significant progress and personal goals for the coming year
Joshua Richter, MD, Tisch Cancer Center at Mount Sinai
Latest:
Dr Richter on the Current State of Bispecific Antibodies in Multiple Myeloma
Joshua Richter, MD, discusses how bispecific antibodies fit into the current treatment armamentarium for patients with multiple myeloma, highlighting his presentation from the 41st Annual CFS®.
Nina Shah, MD, UCSF Helen Diller Family Comprehensive Cancer Center
Latest:
Investigational Agents for Relapsed/Refractory Myeloma
Keith Stewart, MD, ChB, MBA; Sagar Lonial, MD, FACP; Cristina Gasparetto, MD; Joseph Mikhael, MD; and Nina Shah, MD, review additional emerging agents in the pipeline for the treatment of RRMM; including BCMA-targeted bispecific antibodies.
Miguel Gonzalez Velez, MD
Miguel Gonzalez Velez, MD, is a Thoracic Oncologist and member of the Drug Discovery/Phase I Research at Hackensack University Medical Center & John Theurer Cancer Center.
Latest:
Dr Gonzalez Velez on the Role of Tarlatamab As Second-Line Treatment For SCLC
Miguel Gonzalez Velez, MD, discusses the role of tarlatamab as a second-line treatment for small cell lung cancer.
Lauren Meehan Machos, MPH
Lauren Meehan Machos, MPH is Head, Thought Leader Liaison, Strategy & Partnerships Oncology Lead at Nuvalent, Inc.
Latest:
How Unexpected Opportunities Shaped an Oncology Career Beyond the Clinic: With D. Ross Camidge, MD, PhD; and Lauren Meehan Machos, MPH
Camidge and Machos discussed Machos' early career transition from pre-med to sales, to her role in building strategic partnerships with key opinion leaders in oncology.
Jennifer Effie Amengual, MD
Jennifer E. Amengual, MD, is the Herbert Irving Assistant Professor of Medicine in the Division of Hematology and Oncology at Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center.
Latest:
Precision Epigenetic Targeting for Germinal Cancer Lymphomas
Jennifer Effie Amengual, MD, of Columbia University Hebert Irving Comprehensive Cancer Center, discusses precision epigenetic targeting for germinal cancer lymphomas.
Rebecca Zweifler, MD
Rebecca Zweifler, MD, is a Research Fellow of Hematology and Oncology in the Fellowship Program at Atlantic Health System.
Latest:
An Oncology Fellow Reflects on End-of-Life Patient Care
Rebecca Zweifler, MD, pens a personal essay reflecting on her experience with a patient who left a lasting impact on her.
Hervé Tilly, MD, PhD
Latest:
Dr. Tilly on Pola-R-CHP in an Asia Subpopulation of Patients With DLBCL
Hervé Tilly, MD, PhD, discusses the efficacy of polatuzumab vedotin-piiq plus rituximab, cyclophosphamide, doxorubicin, and prednisone in an Asia subpopulation of patients with diffuse large B-cell lymphoma.
Michael J Birrer, MD, PhD
Latest:
Dr Birrer on Molecular Stratification in Endometrial Cancer
Michael J. Birrer, MD, PhD, discusses the benefits of molecular profiling in patients with endometrial cancer, the variety of mutations that have been identified in this disease, and how stratifying patients based on the biomarkers their disease harbors allows for more individualized treatment decisions.